Fungi are an important cause of infection in patients undergoing solid organ transplantation and bone marrow or hematopoietic stem cell transplantation (BMT/HSCT). The incidence and mortality of fungal infections differ according to the organ and the time since transplantation. In the first 30 days after transplantation, yeast (primarily Candida spp.) predominate. After the first month, filamentous fungi, such as Aspergillus spp., are the most frequent agents of infection (1) (2) (3) (4) (5) (6) .
In BMT/HSCT patients, however, invasive aspergillosis has two peaks of incidence: one at one month posttransplantation and another approximately 90 days after the transplant if the patient develops chronic graft versus host disease (7, 8) .
Among solid organ transplantation, liver and lung transplant have the highest risk for fungal infection due to underlying diseases, surgical techniques and the graft itself (4, 9) .
Antifungal prophylaxis use is well established following some transplant types, such as BMT/HSCT and liver (10, 11) . However, few studies have evaluated heart and pancreas transplants. One of the major challenges is the prevention of filamentous fungal infections, especially by Aspergillus spp., in high-risk patients, such as those who have undergone an allogeneic BMT and developed chronic graft versus host disease or undergone a lung transplantation (12, 13) .
To standardize the use of primary prophylaxis in transplant patients, we analyzed the literature related to the following transplants: liver, kidney, heart, lung, and HSCT. The IDSA (Infectious Diseases Society of America) system was used to determine the levels of evidence. N Criterion 2 -at least two of the following risk factors:
antibiotic prophylaxis for spontaneous bacterial peritonitis (SBP) pre-tx, reoperation, ICU admission in the 30 days before the tx, or antibiotic use in the 30 days before the tx.
Kidney transplantation
There are no studies on prophylaxis. Prophylaxis is not recommended (DII). (12, (21) (22) (23) (24) Universal prophylaxis: yes (AI) -Inhaled amphotericin B deoxycholate for 3 months (50 mg + 50 ml of distilled water; 10 ml inhalation twice a day)
Lung transplantation
Targeted prophylaxis: yes, if the recipient or donor has airway colonization by Aspergillus spp. pre-tx or post-tx (associated with amphotericin B inhalation).
First choice*: 400 mg itraconazole orally for 3 months (BIII) Second choice: IV voriconazole (6 mg/kg/day) or oral voriconazole (400 mg/day) for 3 months (CIII) * Advised serum concentration.
Heart transplantation (22)
Prophylaxis not indicated (DII).
5. Hematopoietic stem cell transplant (HSCT) (10, (25) (26) (27) (28) Universal prophylaxis: yes (AI) Fluconazole 400 mg/day IV or oral for 100 days Targeted prophylaxis: yes, for patients under treatment for GVHD First option: amphotericin B deoxycholate 1 mg/kg/day (or equivalent doses of a lipidic formulation) for 100 days (CIII) Second option: itraconazole* 400 mg/day, oral for 100 days (CIII)
Third option: EV voriconazole (6 mg/kg/day) or oral voriconazole (400 mg/day) for 100 days (CIII) ** Advised serum concentration. Controlled and randomized studies have been registered with other azoles, but they were not standardized in the institution or perhaps they are not available in Brazil. (1) (2) (3) (4) (5) (6) . Nos pacientes submetidos a TMO/TCTH, entretanto, a Aspergilose invasiva apresenta dois picos de incidência um no final do primeiro mês e outro aproximadamente 90 dias depois do transplante caso o paciente desenvolva doença do enxerto versus o hospedeiro (7) (8) . Dentre os transplantes de ó rgã o só lidos os que apresentam maior risco para o desenvolvimento de infecçõ es fú ngicas sã o o transplante de fígado e de pulmã o, por questõ es ligadas à s pró prias doenças de base, técnica cirú rgica e enxerto (4,9). O uso de profilaxia antifú ngica já esta bem consolidada para alguns grupos de transplantes como TMO/TCTH e transplantes hepáticos (10, 11) . Contudo, ainda há uma escassez de estudo em transplante de coraçã o e pâ ncreas. O grande dilema, entretanto, é a prevençã o de infecçõ es por fungos filamentosos em especial Aspergillus spp nos pacientes de alto risco como transplante de medula ó ssea alogênico com doença do enxerto contra o hospedeiro (DECH) e transplantados de pulmã o (12, 13) .
Com intuito de padronizar o uso de profilaxia primária em pacientes transplantados, foi analisada a literatura referente aos seguintes transplantes: fígado, rim, coraçã o, pulmã o e TCTH. Para a determinaçã o dos níveis de evidência foi utilizado o sistema da IDSA (Infectious Diseases Society of America).
Recomendaç õ es: N Critério 2 -pelo menos dois dos seguintes fatores de risco: uso de antibió tico profilático para peritonite bacteriana espontâ nea pré-transplante, reoperaçã o, admissã o em unidade de terapia intensiva nos ú ltimos 30 dias antes do transplante, antibió ticos nos ú ltimos 30 dias antes do transplante.
Transplante de Rim
Nã o há estudos sobre profilaxia Profilaxia nã o indicada (DII) 3. Transplante de Pulmão (12, (21) (22) (23) (24) Profilaxia universal: sim (AI) Anfotericina B deoxicolato via inalató ria, por 3 meses (50 mg + 50 ml de água destilada -inalaçã o com 10 ml, 2 vezes por dia) Profilaxia dirigida: sim, se receptor ou doador com colonizaçã o das vias aéreas por Aspergillus spp pré-tx ou pó s-tx (associada à anfotericina B inalató ria) Primeira opçã o: Itraconazol* 400 mg oral por 3 meses (BIII) Tabela 1 -Incidê ncia e mortalidade das Infecç õ es Fú ngicas na populaçã o de pacientes submetidos a transplante de ó rgã os só lidos e TMO/TCTH [1, 4] . 
